We are live on
!
Find out more
CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.99B
1-Year Est. Return
737.95%
This Fund
S&P 500
This Quarter
Est. Return
+57.35%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.79B
AUM Growth
+$267M
(+18%)
Cap. Flow
-$147M
Cap. Flow
% of AUM
-8.23%
Top 10 Holdings %
Top 10 Hldgs %
60.02%
Holding
83
New
11
Increased
14
Reduced
6
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MoonLake Immunotherapeutics
MLTX
|
+$33.6M |
| 2 |
Zentalis Pharmaceuticals
ZNTL
|
+$26.3M |
| 3 |
CBAY
Cymabay Therapeutics
CBAY
|
+$23.5M |
| 4 |
Vaxcyte
PCVX
|
+$18.5M |
| 5 |
EyePoint Inc
EYPT
|
+$18.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
+$178M |
| 2 |
Pliant Therapeutics
PLRX
|
+$38.4M |
| 3 |
RAIN
Rain Oncology Inc. Common Stock
RAIN
|
+$26M |
| 4 |
ETNB
89bio
ETNB
|
+$25.5M |
| 5 |
Monte Rosa Therapeutics
GLUE
|
+$22.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.17% |
| 2 | Financials | 0.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
MoonLake Immunotherapeutics
MLTX
$1.62B
| $415M | 23.26% |
8,142,100
+1,249,999
| +18% | +$33.6M |
|
|
AMAM
2
DELISTED
Ambrx Biopharma Inc
AMAM
| $158M | 8.87% |
9,616,155
+1,116,155
| +13% | +$14M |
|
|
APLS
3
DELISTED
Apellis Pharmaceuticals
APLS
| $119M | 6.69% |
1,310,000
-50,000
| -4% | -$4.31M |
|
4
Biomea Fusion
BMEA
$88.2M
| $78.4M | 4.39% |
3,570,872
| – | – |
|
5
BridgeBio Pharma
BBIO
$16.1B
| $71.7M | 4.02% |
4,169,179
-388,235
| -9% | -$5.84M |
|
|
ACLX
6
DELISTED
Arcellx
ACLX
| $63.2M | 3.54% |
2,000,000
+400,000
| +25% | +$15.3M |
|
7
Immuneering
IMRX
$274M
| $42.6M | 2.39% |
4,204,364
+1,818,183
| +76% | +$17.5M |
|
|
CBAY
8
DELISTED
Cymabay Therapeutics
CBAY
| $41.6M | 2.33% |
3,800,000
+2,528,571
| +199% | +$23.5M |
|
9
Protagonist Therapeutics
PTGX
$8.92B
| $41.4M | 2.32% |
1,500,000
-200,000
| -12% | -$5.01M |
|
10
Enliven Therapeutics
ELVN
$3.85B
| $39.5M | 2.21% |
1,936,133
| – | – |
|
|
11
Vaxcyte
PCVX
$8.08B
| $33.2M | 1.86% |
665,000
+390,000
| +142% | +$18.5M |
|
12
Design Therapeutics
DSGN
$788M
| $32.4M | 1.82% |
5,150,000
| – | – |
|
|
13
Zentalis Pharmaceuticals
ZNTL
$350M
| $30.9M | 1.73% |
+1,095,000
| New | +$26.3M |
|
14
Erasca
ERAS
$6.48B
| $29.8M | 1.67% |
10,813,246
| – | – |
|
|
RNAM
15
DELISTED
Avidity Biosciences
RNAM
| $29M | 1.62% |
2,612,115
| – | – |
|
16
Cabaletta Bio
CABA
$444M
| $28.7M | 1.61% |
2,221,739
+400,000
| +22% | +$4.34M |
|
|
17
EyePoint Inc
EYPT
$1.08B
| $27.8M | 1.56% |
3,200,000
+2,974,935
| +1,322% | +$18.2M |
|
18
Olema Pharmaceuticals
OLMA
$1.03B
| $27.8M | 1.56% |
3,082,000
| – | – |
|
|
JBIO
19
Jade Biosciences
JBIO
$1.22B
| $26.8M | 1.5% |
44,620
| – | – |
|
20
Tarsus Pharmaceuticals
TARS
$2.6B
| $25.7M | 1.44% |
1,421,422
| – | – |
|
|
ETNB
21
DELISTED
89bio
ETNB
| $25.6M | 1.43% |
1,350,000
-1,450,000
| -52% | -$25.5M |
|
22
Axsome Therapeutics
AXSM
$12.1B
| $24.4M | 1.37% |
340,000
+40,000
| +13% | +$2.95M |
|
23
Structure Therapeutics
GPCR
$3.52B
| $24M | 1.34% |
576,373
| – | – |
|
24
Edgewise Therapeutics
EWTX
$4.42B
| $22.8M | 1.28% |
2,946,887
| – | – |
|
25
Viridian Therapeutics
VRDN
$2.2B
| $20.2M | 1.13% |
850,000
| – | – |
|
Similar funds
SC
RMCM
RCM
LGM
MYAM
CCA
LBC
C
Cormorant Asset Management's Q2 2023 Portfolio in Review
As of Q2 2023, Cormorant Asset Management held 83 positions worth $1.79B, up 18% from $1.52B the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Cormorant Asset Management withdrew a net $147M in Q2 2023, closing 19 positions and reducing 6 holdings. Its most notable exit was Prometheus Biosciences, Inc. Common Stock, an estimated $178M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier, followed by Financials.
Against the trend, Cormorant Asset Management opened a new position in Zentalis Pharmaceuticals worth $30.9M.
- Cormorant Asset Management's largest Q2 2023 buy was Zentalis Pharmaceuticals: 1,095,000 shares worth $30.9M.
- Cormorant Asset Management added most to MoonLake Immunotherapeutics in Q2 2023, an estimated $33.6M increase.
- Cormorant Asset Management's biggest Q2 2023 reduction was 89bio, cutting an estimated $25.5M.
- Cormorant Asset Management fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $178M.
- Cormorant Asset Management's ten largest holdings make up 60% of its $1.79B portfolio in Q2 2023.
- Cormorant Asset Management opened 11 new positions and closed 19 in Q2 2023.
- Cormorant Asset Management's portfolio value rose 18% quarter-over-quarter to $1.79B.
Based on Cormorant Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.